London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You might as well short IMM or sell and buy back cheaper in a month following the RI.
Someone somewhere knows and Mr Market is speaking
Directors have hardly any skin in the game, they use death spiral finance that is proven on 3 consecutive occasions to destroy value for shareholders, an almighty shafting is on the way here imo price action doesn’t lie when it’s coupled with total silence from the bod
Reading previous RNS Immu pharma has done a lot and is in better position than previous with Phase 3 trail preparation on going.This share is not for weak hearten and quick turn around investors.Time will reward for LTH.If you are in rush to make money Immu pharma is not that your looking to invest.Patience needed for this kind of companies.I'm 100% convince with the Lupus huge potential and that this will multi-bagger with lots of news to flow this year.Especially we have US Avion partner investing of Trail.Everything positive.No panic for me.GOOD LUCK LTH.
"...an almighty shafting is on the way here imo "
If more shares are issued at say 1p then the almighty price action has already been underway and happening, in anticipation of a further fund raise .....it has been happening for weeks , hence down 40%
Better to invest once and if they actually have a revenue flow.
Buying IMM you’re better off putting it on red or black. At least you can lose and just bail out. You could have another 5 years of equity raises here at absolute fractions of a penny.
Their R&D will be hoovered up once they’re bankrupt
'Better to invest once and if they actually have a revenue flow.'
IS that why you invested in Incanthera Last month ?
What IS the current revenues of Incanthera ?
Did they just do a placing to cover their overheads ?
Whatever ..
You must have bought for the 'Potential '
Not a chance they will be able to raise at 1p now Imo brokers want at least a 20% discount to get a placing away sometimes up to 50%. The market is never wrong and radio silence from the bod tells its own story
Lambo222,
Whilst we await further news from the BOD , it would be nice to have a bit of radio silence about placings, bankruptcy etc etc ..
I think WE are all aware of the possible outcomes , so please give it a rest .
Best regards
" Imo brokers want at least a 20% discount to get a placing away sometimes up to 50%"
If they found direct investors, through their own NOMAD Spark , they wouldn't need other Brokers , and Retail goes through a platform like Winterflood Retail Access Platform. They normally give Spark shares and maybe Warrants
I cannot see them doing an expensive RI ...they will try and pinpoint specific investors who invest in this kind of business ...IMO
Yes well they haven't managed that so far hence using Lanstead to fund, someone is selling heavily that’s clear
Lambo
Now that you have administered the last rites on Immupharma and urge investors to cash out before another death spiral placing, you must remember that at the current 1p , investors have in effect lost almost everything so why worry about a drop to .5p unless you wish to depart with some beer money.
With £65 million in tax losses, patents and 2 Phase 3 trials in the offing surely any scrap value is more than a couple of £million plus Immupharma's shares in Incanthera.
I have seen many AIM companies in worse straits than Immupharma and have survived and prospered.
I am going to see this out one way or the other.
ATB
Mr Market price was 170p a few years ago-now his price is 1p-Mr Marker knows what he is doing!
I have 1 m shares- If there is a placing at 1p or below I will buy whatever it takes to avoid personal dilution. The fundamentals are still there-cash is the major consideration-maybe.
I am disappointed about the news flow. I now wonder whether the Chairman/CEO is spreading himself to thin with him chairing INC as well. If we do not get news flow soon I may suggest that we do a VAL and withdraw shareholder support from him being a Director of IMM.
I was disappointed that none of the mainstream Executive Directors participated in the recent placing at 2p.
However, I remember Independent Insurance amongst others where the MD and Deputy MD constantly purchased large numbers of shares while fraudulently under reserving causing the company to crash.
Will return to this when the position becomes clearer.
GLA
Yes an EGM to remove the board wouldn’t be a bad idea imo, but only once Lanstead have sold all their shares as clearly they wouldn’t support it as they are making a fortune from IMM
I would just be patient while Landstead sell down....it is hardly unexpected
It wasn't that long ago that posters here were very positive about the appointment of Dr Reilly..... and yet he seems to have been forgotten
" Dr Laurence Reilly as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.
He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry."